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Abstract
Background: Increased functionality of efflux transporters at the blood-brain barrier may contribute to decreased
drug concentrations at the target site in CNS diseases like epilepsy. In the rat, pharmacoresistant epilepsy can be
mimicked by inducing status epilepticus by intraperitoneal injection of kainate, which leads to development of
spontaneous seizures after 3 weeks to 3 months. The aim of this study was to investigate potential changes in P-
glycoprotein (P-gp) expression and functionality at an early stage after induction of status epilepticus by kainate.
Methods: (R)-[
11C]verapamil, which is currently the most frequently used positron emission tomography (PET)
ligand for determining P-gp functionality at the blood-brain barrier, was used in kainate and saline (control) treated
rats, at 7 days after treatment. To investigate the effect of P-gp on (R)-[
11C]verapamil brain distribution, both groups
were studied without or with co-administration of the P-gp inhibitor tariquidar. P-gp expression was determined
using immunohistochemistry in post mortem brains. (R)-[
11C]verapamil kinetics were analyzed with approaches
common in PET research (Logan analysis, and compartmental modelling of individual profiles) as well as by
population mixed effects modelling (NONMEM).
Results: All data analysis approaches indicated only modest differences in brain distribution of (R)-[
11C]verapamil
between saline and kainate treated rats, while tariquidar treatment in both groups resulted in a more than 10-fold
increase. NONMEM provided most precise parameter estimates. P-gp expression was found to be similar for kainate
and saline treated rats.
Conclusions: P-gp expression and functionality does not seem to change at early stage after induction of
anticipated pharmacoresistant epilepsy by kainate.
Background
About 30-40% of all people with epilepsy do not become
fully seizure free with present medication, even when
treated at the maximal tolerated dose. This pharmacore-
sistance is particularly prominent in partial epilepsies
and some severe syndromes in infants, but essentially it
can occur in nearly all types of epilepsies and epileptic
syndromes. In addition, unresponsiveness in these
patients is not limited to a specific drug or drug class,
but occurs with the complete range of antiepileptic
drugs (AEDs) [1,2].
For a drug to exert its effect, it has to be distributed
to its target at a therapeutic concentration and must be
able to interact with the target. Several different
mechanisms influence transport across the blood-brain
barrier (BBB); i.e. passive diffusion, as well as active
influx and active efflux processes. P-glycoprotein (P-gp)
is one of the most important efflux transporters of exo-
genous substances at the BBB [3,4]. Several studies, both
clinical and pre-clinical, have indicated that P-gp
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target site AED concentrations in the brain [5-15]
A number of studies have shown that BBB P-gp
expression is upregulated in epilepsy [10,12,16-20].
Therefore, it had been hypothesized that the observed
loss of efficacy of AEDs may be caused by limited brain
distribution in pharmacoresistant epilepsy caused by
P-gp mediated efflux from the brain [21]. This hypothesis
has been criticised by some authors [22].
Temporal Lobe Epilepsy is the most common form of
epilepsy in humans and in more than half of the
patients it is associated with pharmacoresistance. This
condition can be mimicked in the rat by inducing status
epilepticus (SE), e.g. by intraperitoneal injection of kai-
nate [23]. In the majority of animals this leads to devel-
opment of spontaneous seizures after about three weeks.
However as not all patients and not all SE subjected rats
become pharmacoresistant it is an important question
whether this variability is related to the degree of
increased P-gp expression and whether this parameter
can be used as a predictor for development of
pharmacoresistance.
The aim of this study was to investigate potential
changes in P-gp expression and functionality in vivo
with positron emission tomography (PET). For this
purpose a condition at which there is clear increased
P-gp expression would be most suitable. In SE models
the most prominent increase in P-gp expression has
been reported between 2-7 days after SE induction
[6,20,24]. The well established PET ligand for deter-
mining P-gp functionality at the BBB, (R)-[
11C]verapa-
mil [25-34], was used in kainate and saline treated
rats, at 7 days after injection. To investigate the speci-
fic contribution of P-gp at the BBB, both groups were
studied without or with co-administration of the P-gp
inhibitor tariquidar. P-gp expression was further deter-
mined using immunohistochemistry in post mortem
brains to investigate the relationship between expres-
sion and functionality. (R)-[
11C]verapamil kinetics in
these groups were analyzed using the common data
analysis approaches used in PET (Logan analysis, com-
partmental modelling of individual profiles) as well as
by population mixed effects modelling (NONMEM) in
which sources of variability can be better addressed. In
addition, covariate analysis can be integrated in the
NONMEM data analysis which is a valuable tool to
identify the specific origin of variability when different
animal types and treatments are used.
Methods
Animals
Adult male Sprague-Dawley rats (n = 50, Harlan, Horst,
The Netherlands) weighing 200-224 g at arrival were
housed in groups of 5-6 per cage until treatment. They
were kept at a constant temperature of 21°C and at a 12
h light/dark cycle, in which lights were switched on
at 8:00 AM. Animals had unrestricted access to food
(Teklad Global 16% Protein Rodent Diet, Harlan, Madi-
son, WI, USA) and water. Animal procedures were per-
formed in accordance with Dutch laws on animal
experimentation. All experiments were approved by the
Ethics Committee for Animal Experiments of Leiden
University (approval number UDEC08178). After
approximately one week of habituation and 7 days prior
to PET investigation rats were treated with either kainic
acid (5 mg/mL) or saline. Kainic acid was administered
repeatedly as a 10 mg/kg (2 mL/kg) i.p. injection
followed by 5 mg/kg (1 mL/kg) i.p. every 30-60 minutes
until stage IV seizures according to Racine’s scale [35]
occurred, or when a total amount of 30 mg/kg kainic
acid was reached. Control rats were treated with 3 saline
i.p. injections using the same volumes as for the kainate
treated rats, 30 minutes apart. After treatment rats were
housed individually.
Chemicals
Tariquidar was obtained from API Services Inc (West-
ford, MA, USA), kainic acid and Triton X-100 from
Sigma-Aldrich (Zwijndrecht, The Netherlands), isoflurane
from Pharmachemie BV (Haarlem, The Netherlands), 5%
glucose in saline from hospital pharmacy of the University
Medical Centre Leiden (UMCL, Leiden, The Netherlands),
Tissue-Tek from Sakura Finitek Europe (Zoeterwoude,
The Netherlands), iso-methy l b u t a n ea n dP - g pp r i m a r y
antibody C219 from VWR (Amsterdam, The Nether-
lands), bovine serum albumin from ICN Biomedicals
(Zoetermeer, The Netherlands), rabbit and swine serum
from Tebu-Bio (Heerhugowaard, The Netherlands), sec-
ondary antibody (Rabbit-anti-Mouse, bRaM) from Dako
(Heverlee, Belgium) and streptavidin and 3,3-diaminoben-
zidine (DAB)-kit from Brunschwig Chemie Vector Labs
(Amsterdam, The Netherlands). All starting materials for
(R)-[
11C]verapamil syntheses were obtained commercially
and were of reagent grade.
PET experiments
Rats were anesthetized via a nose mask with isoflurane,
4% and 2% induction and maintenance, respectively, in
oxygen 1 L/minute. The femoral vein and artery were
cannulated 1-2 hours prior to PET scanning for admin-
istration of (R)-[
11C]verapamil and tariquidar, and blood
sampling, respectively.
(R)-[
11C]verapamil was synthesized as previously
described [36] yielding a solution of 1-3 GBq in
around 10 mL 10% ethanol in saline. The specific
activity was 56 ± 26 (mean ± s.d.) GBq/μmole. Rats
from the different groups were randomly assigned to
experimental days and scanned in pairs for 60 minutes
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Research Tomograph (HRRT, CTI/Siemens, Knoxville,
TN, USA) [37]. For attenuation and scatter correction,
transmission scans were acquired prior to the start of
the emission scan using a 740 MBq 2-dimensional
(2D) fan-collimated
137Cs (662 keV) moving point
source [38]. The emission scan was started 30 seconds
before an injection of 20.8 ± 4.5 MBq (0.15-0.3 mL)
no-carrier added (R)-[
11C]verapamil (Table 1). Half of
the rats were injected intravenously with tariquidar, 15
mg/kg (3 mL/kg) dissolved in a vehicle consisting of
5% glucose in saline, as a bolus dose 20-30 minutes
prior to the (R)-[
11C]verapamil injection. The other
half was treated only with vehicle (3 mL/kg). Immedi-
ately after the (R)-[
11C]verapamil scan, 8.9 ± 1.8 MBq
(0.15-0.3 mL) [
18F]-2-fluoro-2-deoxy-D-glucose
(
18FDG) was injected and a new 60 minutes scan was
started. The purpose of the
18FDG scan was to outline
the brain to aid in defining regions of interest. The
HRRT scanner acquires data in list mode, enabling
post-scan definition of the frame sequence. The final
frame sequence used for analysis was 6 × 10, 2 × 30, 3
× 60, 2 × 150, 2 × 300 and 4 × 600 seconds. Studies
were reconstructed using an iterative 3 D ordered-sub-
sets weighted least-squares (3D-OSWLS) method with
8 iterations and 16 subsets [39]. No post-reconstruc-
tion filtering was applied. Point source resolution var-
ied across the field of view from approximately 2.3 to
3.2 mm (FWHM) in the transaxial direction and from
2.5 to 3.4 mm in the axial direction [37].
During the (R)-[
11C]verapamil scan, arterial blood
samples of 0.1 mL were obtained at 0.5, 1, 3, 5, 10, 15,
20, 30, 45 and 60 minutes after injection. Plasma was
obtained by centrifugation at 5000 rpm for 5 minutes
a n da c t i v i t yi np l a s m aa n dw h o l eb l o o ds a m p l e sw a s
measured in an automated 1282 Compugamma CS Uni-
versal Gamma Counter (LKB Wallac, Turku, Finland),
cross-calibrated against the PET scanner. In addition,
blood samples of 0.3 mL were obtained at 10, 30 and 60
minutes and analysed for metabolism of (R)-[
11C]verapa-
mil. A further 0.3 mL blood sample for the measure-
ment of tariquidar concentration was obtained after the
end of the
18FDG scan and analyzed using liquid chro-
matography tandem mass-spectrometry (LC/MS). Rats
were euthanized under anaesthesia by decapitation
immediately after the final blood sample.
Metabolite analysis
Metabolite analysis in plasma was performed as
described previously [40]. In short, using solid phase
extraction, three fractions were determined for each
plasma sample: (R)-[
11C]verapamil, N-dealkylated pro-
ducts and O-demethylated products (non-polar metabo-
lite fraction) and N-demethylated products (polar
metabolite fraction).
P-glycoprotein expression
P-gp expression in brain capillaries was measured
according to a previously published protocol after some
minor changes [41]. In short, after decapitation, the
brain was isolated and transferred to an aluminium foil
cup filled with Tissue-Tek, embedding the brain, and
placed in an iso-methylbutane containing glass beaker in
liquid nitrogen. After 1-2 minutes the brain was com-
pletely frozen and thereafter stored at -80°C until
further analysis. The frozen brains were cut in coronal
sections, 30 μm, using a Leica CM1900 cryostat (Leica
Microsystems B.V., Rijswijk, The Netherlands). The sec-
tions were post fixed in acetone and stored at -20°C
until immunohistological staining. Sections selected
from the brain between -2.3 mm to bregma, were cho-
sen for immunohistochemistry [42].
Staining of brain sections from all rats were processed
simultaneously in the same reaction trays to obtain
comparable staining intensity. Sections were thoroughly
washed for 3 × 5 minutes in 0.5 M tris-buffered saline
(TBS, 9% NaCl, pH 7.6) at room temperature. To inhibit
endogenous peroxidase and reduce background staining,
sections were incubated for 30 minutes in 0.5% H2O2 in
TBS. Again, sections were washed 3 × 5 minutes in 0.5
M TBS. To block interaction with other substrates, a
solution containing 3% bovine serum albumin (BSA),
11% normal rabbit serum and 0.3% Triton X-100, was
added and incubated for 60 minutes at room
Table 1 Number of animals (n) with weight at the time of PET scanning and injected doses of (R)-[11C]verapamil and
18FDG in the different treatment groups (mean ± s.d)
Saline and vehicle
treated
Kainate and vehicle
treated
Saline and tariquidar
treated
Kainate and tariquidar
treated
All
groups
n1 0 1 1 1 0 1 1 4 2
Body weight (g) 327 ± 26 292 ± 33 326 ± 25 293 ± 24 308 ± 31
R-[
11C]verapamil
(MBq)
22.3 ± 3.9 21.4 ± 4.8 22.1 ± 3.9 19.4 ± 5.1 20.8 ± 4.5
18FDG (MBq) 9.6 ± 2.1 8.5 ± 1.9 9.3 ± 1.6 9.1 ± 1.7 8.9 ± 1.8
Of the original 50 animals, 8 animals were discarded; 4 died as a result from the kainate treatment, 1 did not respond to kainate treatment, and 3 were excluded
for technical reasons, such as movement in the scanner or extra vascular tracer injection.
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night at 4°C in 1:100 monoclonal mouse primary anti-
body C219 in carrier medium (containing 1% BSA, 1%
rabbit serum and 0.3% Triton X-100 in TBS). After
overnight incubation, sections were washed 3 × 10 min-
utes in 0.5 M TBS at room temperature. Next, sections
were incubated for 90 minutes in 1:200 biotin-conjugate
Rabbit-anti-Mouse (bRaM) secondary antibody in the
same carrier solution as the primary antibody men-
tioned above. Sections were washed 3 × 5 minutes in
0.5 M TBS and incubated for 90 minutes in 1:375 in 0.5
M TBS solution, after which they were washed 3 × 5
minutes in 0.5 M TB (pH 7.6) instead of TBS to avoid
possible interaction between saline and 3,3-diaminoben-
zidine (DAB). Sections were incubated for 10 minutes in
DAB with 0.03% H2O2 and then washed 2 × 5 minutes
in 0.5 M TB and 1× in ultrapurified water (ELGA, Ede,
The Netherlands). Slides were air-dried and, on the next
day, cover slipped with Entallan (Merck, Darmstadt,
Germany).
Images of the stained sections were obtained with a
Leica DM 600B microscope (Leica Microsystems). All
analyses were performed using the freely available soft-
ware Image J [43]. Two measurements, the P-gp labelled
surface area and its optical density, were performed on
two sections per animal and region in the regions of the
cortex and hippocampus CA1. Both the labelled surface
area and optical density value was obtained by first
choosing a global threshold value, used for all slides.
Only grey values above this threshold were assumed to
result from P-gp staining. In the area method, the total
number of pixels above the threshold was summed. For
the optical density, the mean grey value was measured
for each slide and the background, specific for that
particular slide, was subtracted from the mean value.
Data analysis
PET image data were analyzed using the freely available
software package Amide 0.8.22 [44]. Time-activity
curves in whole brain where obtained by drawing a
volume of interest (VOI) in 4 adjacent transaxial planes
of the
18FDG images summed over 60 minutes, includ-
ing cortical and central structures. The final VOI
volume was 127 μL. Other VOIs were drawn in cerebel-
lum (3 planes) and liver (3 planes), resulting in VOI
volumes of 49 and 57 μL, respectively. Next, VOIs were
transferred to the dynamic (R)-[
11C]verapamil image
sequence, generating corresponding time-activity curves.
Whole brain and cerebellum time-activity curves were
used for analysis of (R)-[
11C]verapamil kinetics in brain.
To correct for an intravascular contribution, radioactiv-
ity measured in whole blood was exponentially interpo-
lated to obtain blood radioactivity values at each mid
f r a m et i m ep o i n ta n dt h e ns u b t r a c t e df r o mt h eb r a i n
time-activity curves, assuming that cerebral blood
volume was 3% of the total brain volume [45].
Liver time-activity curves, obtained from the PET
images, and plasma time-activity curves, obtained from
the plasma samples, were checked for any irregularities
pointing to e.g. extravascular injection. If irregularities
were found, the animal was excluded from further
analysis.
Plasma time-activity curves were corrected for tracer
metabolism before they were used as input for kinetic
modelling. As metabolite fractions were not measured at
each plasma time point, linear regression was used to
estimate the fraction of intact (R)-[
11C]verapamil at all
blood sampling time points. The activity in each plasma
sample was then multiplied with the fraction of intact
(R)-[
11C]verapamil. Two types of corrections were used:
(1) complete metabolite correction and (2) correction
only for polar metabolites. The rationale for the second
correction was that non-polar metabolites of (R)-[
11C]
verapamil are thought to have similar kinetics as
(R)-[
11C]verapamil itself [46]. Mathematically, this is
described by the following equations:
CCf pm =∗ (1)
where Cp is the concentration of the plasma input
function as used for modelling purposes, Cm the (total)
plasma concentration as measured in the gamma coun-
ter and f the fraction of unchanged (R)-[
11C]verapamil.
Here, f is a value between 0 and 1, given by:
f
(R)
=
_[ C]verapamil activity 
Total plasma activity
11
(2a)
for complete metabolite correction, or
f
(R)
=
+
_[ C]verapamil activity
Total plasma activity
[C ] n o
11
11 n n - polar metabolite activity
Total plasma activity
(2b)
for correction of polar metabolites only
Finally, data were analysed without a correction for
labelled metabolites, i.e. assuming f=1 . For modelling
of individual profiles (see section below), Cp was linearly
interpolated to obtain plasma activity values at the same
time points as in the brain, i.e. the mid frame time
points.
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The models described in this section were fitted to indi-
vidual data from each animal. To obtain a model-inde-
pendent estimate of the brain-to-blood partition
coefficient Kp (often referred to as volume of distribu-
tion, VT, in PET literature), Logan graphical analysis
[47] was used. In addition, the influx rate constant K1
was estimated from Logan analysis. PET data were also
fitted using standard compartmental models, i.e. a 1 tis-
sue (brain) compartment model with 2 rate constants
(1T2k) and a 2 tissue (brain) compartment model with
4 rate constants (2T4k) [48]. In the 1T2k model the two
rate constants describe transport across the BBB, whilst
the 2T4k model also includes two rate constants
describing the exchange between fast and slow equili-
brating compartments in the brain. The model with the
lowest value of the Akaike information criterion (AIC)
was considered the best [49]. Rate constants obtained
for the different rat groups were compared using a t-test
with Bonferroni correction for multiple comparisons.
Dedicated analysis programs were written within the
MATLAB 6 (Mathworks, Natick, MA, USA) software
environment.
Population mixed effects modelling
Nonlinear mixed effects modelling, using NONMEM VI
(GloboMax LLC, Hanover, MD, USA), provide a tool
for analyzing repeated measurements data in which the
relationship between the explanatory and response vari-
ables can be modeled as a single function, allowing the
parameters to differ between individuals. In addition,
these techniques recognize that the variability associated
with the response variable for a given individual may
depend on the response value in a way that is similar
for all individuals. This could be due, for example, to
properties associated with measurement error.
Data from all rats was processed simultaneously. The
subroutine ADVAN 9 and first-order conditional esti-
mation with interaction were used throughout the mod-
elling procedure. Model selection was based on the
objective function value (OFV; with the lowest value
corresponding to the best model), model parameter
uncertainty and visual analysis using software Xpose 4
[50] implemented in R 2.7.1 (The R foundation for Sta-
tistical Computing) accessed from Census [51]. For
nested models, OFV reductions of 3.83, 6.63 and 10.83
u n i t sc o r r e s p o n dt oi m p r o v e df i t sa tp<0 . 0 5 ,p<0 . 0 1
and p < 0.001 levels, respectively. The inter-individual
variation of a parameter was described by the exponen-
tial variance model:
  ip o p i =∗ exp( ) (3)
where θi is the parameter in the i
th animal, θpop the
parameter in a typical animal and hi the inter-animal
variability, which is assumed to be normally distributed
around zero with a standard deviation ω.E q u a t i o n( 3 )
provides a means to distinguish the parameter value for
the i
th animal from the typical value predicted from the
regression model.
The NONMEM model was constructed in two steps.
In the first step, a pharmacokinetic model for (R)-[
11C]
verapamil plasma concentrations was developed. One,
two and three compartment models were evaluated.
Treatment (tariquidar or vehicle), rat group (saline or
kainate treated) and animal weight were defined as cov-
ariates to study their effects on the parameter estimates.
In the second step the model was extended to include
brain (R)-[
11C]verapamil PET data, while allowing the
plasma estimates to freely change from the values
obtained in the first step. Again, one and two compart-
ment models were evaluated, and treatment, rat group
and animal weight were included as covariates. A step-
wise forward addition and backward deletion approach
was applied to test the significance for covariate inclu-
sion. Proportional error models were included for the
residual variability.
Results
Kainate treatment
Kainic acid treatment resulted in stage IV-V seizures in
all rats, except one who did not show any epileptic
behaviour after 30 mg/kg kainic acid. Typically 3 injec-
tions, i.e. 20 mg/kg, were needed and SE was usually
reached within 20 minutes after the last injection. Rats
usually displayed seizures for 1-2 hours. The seizures
were not interrupted by any anti-epileptic drug. Due to
the design of this study it was not possible to determine
whether these animals eventually would have developed
spontaneous epilepsy, but the signs and symptoms dur-
ing and after SE were very similar to those observed in
previous studies where animals did develop epilepsy.
Four rats died as a result of kainic acid treatment. The
final numbers of successfully scanned rats in each
group, together with their average weight on the experi-
mental day, are shown in Table 1.
(R)-[
11C]verapamil metabolite analysis
Metabolite analysis showed no differences between
plasma metabolite fractions in the various groups of
rats. The fractions of intact (R)-[
11C]verapamil were
(mean ± s.d.) 0.79 ± 0.05, 0.58 ± 0.07 and 0.39 ± 0.08 at
10, 30 and 60 minutes, respectively. The summed frac-
tions of intact (R)-[
11C]verapamil and its
11C labelled
non-polar labelled metabolites were 1.00 ± 0.00, 0.97 ±
0.02, 0.91 ± 0.06 at 10, 30 and 60 minutes, respectively.
For tariquidar treated rats, complete metabolite correc-
tion of the plasma curve (Material and methods, Equa-
tion 2a) resulted in better fits and less variation in
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metabolite alone (Equation 2b) or no correction at all.
For vehicle rats, the different corrections resulted in
only minor differences. In the final analysis complete
metabolite correction (Equation 2a) was used and all
estimates reported are based on this correction.
(R)-[
11C]verapamil brain uptake without tariquidar
treatment
Uptake of (R)-[
11C]verapamil in the brain was homoge-
neous, but time-activity curves for the cerebellum VOI
showed somewhat faster uptake and washout than those
for the whole brain VOI (data not shown). Modelling
was performed using the whole brain VOI time-activity
curves. Average whole brain time-activity curves,
expressed in standardized uptake value (SUV, radioactiv-
ity normalized to injected dose and animal weight), are
shown in Figure 1. Three of the scanned rats were
excluded due to movement in the scanner (n = 1) or
extravascular tracer injection (n = 2).
No difference in brain to blood concentration ratio, Kp,
was found between saline treated control and kainate
treated rats. All modelling approaches resulted in similar
estimates of Kp, with the 1T2k model providing lower Kp
estimates than Logan analysis, the 2T4k model and the
two compartment population model (Table 2). The dif-
ferent modelling approaches (see Material and Methods)
also resulted in similar K1 estimates with no significant
differences between saline and kainate treated rats. AIC
values were used to compare the performance of the
1T2k and 2T4k models. In general, AIC values were simi-
lar for 1T2k and 2T4k models, with an average difference
of 0.5% in favour of the 1T2k model. Visual inspection,
however, indicated that, in most cases, better fits were
Figure 1 Mean whole brain uptake of (R)-[
11C]verapamil, expressed as SUV (radioactivity normalized to injected dose and rat weight),
as function of time in the four rat groups. Vertical bars represent standard deviation. No difference was found in the profiles between vehicle
co-administered saline and kainate treated animals. Somewhat slower kinetics was observed in the kainate treated compared to the saline
treated rats that were also co-administered with tariquidar.
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variation in the parameter estimates, however, was larger
for the 2T4k model than for the 1T2k model.
P-gp blockage by Tariquidar co-administration
Tariquidar plasma concentrations were not significantly
different between saline and kainate treated rats. At 2
hours after tariquidar administration the concentrations
(mean ± s.d.) were 1.8 ± 0.3 and 1.6 ± 0.3 μg/mL in the
saline and kainate group, respectively. Tariquidar
co-administration resulted in a 10- to 11-fold increase in
the brain-to-plasma concentration ratio, Kp, regardless of
the modelling approach used. This increase was of simi-
lar magnitude for whole brain and cerebellum. In addi-
tion, after tariquidar treatment, there was no significant
difference in Kp between saline and kainate treated rats.
Both the 1T2k and the 2T4k model showed that after tar-
iquidar co-administration, the (R)-[
11C]verapamil trans-
port into the brain, K1 was strongly increased, both in
kainate treated and saline treated rats (Table 2). However
Table 2 Mean (± standard deviation) of (R)-[11C]verapamil parameter estimates for the different rat groups obtained
using various modelling approaches (*** p < 0.001, ** p < 0.01, * p < 0.05., not significant (ns) p> 0.05)
Vehicle treated Tariquidar treated
Parameter
estimates
Group
1:
Saline
Group 2:
Kainate
Group 1 vs
Group 2
Group 3:
Saline
Group 4:
Kainate
Group 3 vs
Group 4
Group 1 vs
Group 3
Group 2 vs
Group 4
Model - Logan
K1 (mL· mL
-1· min
-
1)
0.06
(0.02)
0.06 (0.02) ns 0.85 (0.16) 0.74 (0.18) ns *** ***
Kp (mL· mL
-1) 1.04
(0.19)
1.00 (0.13) ns 10. 9 (1.3) 11.7 (1.3) ns *** ***
Model - 1T2K
K1 (mL· mL
-1· min
-
1)
0.06
(0.03)
0.07 (0.03) ns 0.93 (0.19) 0.66 (0.18) *** *** ***
k2 (min
-1) 0.08
(0.04)
0.08 (0.04) ns 0.09 (0.02) 0.06 (0.02) ns ns ns
Kp (mL· mL
-1) 0.81
(0.14)
0.82 (0.12) ns 10.4 (1.0) 10.6 (1.4) ns *** ***
Model -2T4K
K1 (mL· mL
-1· min
-
1)
0.07
(0.04)
0.08 (0.04) ns 1.21(0.30) 0.81 (0.27) *** *** ***
k2 (min
-1) 0.16
(0.15)
0.24 (0.26) ns 0.73 (0.66) 0.43 (0.35) ns * ns
k3 (min
-1) 0.11
(0.14)
0.19 (0.30) ns 0.93 (0.75) 0.84 (0.65) ns ** *
k4 (min
-1) 1.08
(1.56)
0.49 (0.96) ns 0.20 (0.05) 1.13 (1.82) ns ns ns
Kp (mL· mL
-1) 1.17
(0.65)
1.12 (0.40) ns 11.0 (1.1) 11.1 (1.5) ns *** ***
Model -2 comp
PopPK
a
K1 (mL· mL
-1· min
-
1)
0.10
(0.02)
0.10 (0.02) ns 0.75 (0.14) 0.62 (0.12) *** *** ***
k2 (min
-1) 0.25
(0.08)
0.25 (0.08) ns 0.10 (0.04) 0.08 (0.03) * *** ***
k3 (min
-1) 0.10
(0.03)
0.10 (0.03) ns 0.04 (0.02) 0.03 (0.01) ns *** ***
k4 (min
-1) 0.06
(0.02)
0.06 (0.02) ns 0.06 (0.02) 0.06 (0.02) ns ns ns
Kp (mL· mL
-1) 0.97
(0.21)
0.97 (0.21) ns 11.6 (2.6) 11.6 (2.6) ns *** ***
arate constants were calculated based on the model estimates shown in Table 3 as follows: K1 =Q in/Vc(Vc/Vbr1+2), k2 =Q out/Vbr1,k 3 =Q br/Vbr1 and k4 =Q br/Vbr2.
The population model is shown in Figure 3. The reader is referred to Gunn, et al. (2001) for a description of the 1T2k and 2T4k models and to Logan, et al. (1990)
for a description of the Logan analysis.
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Page 7 of 16K1 did not increase to the same extent in both groups, as
it was significantly (p < 0.001) lower in kainate compared
to saline treated rats. In addition, the transport out of the
brain, k2, was lower in tariquidar co-administered kainate
treated rats compared with the tariquidar co-adminis-
tered saline treated rats, but the difference did not reach
significance. AIC values were lower (2.6%) for the 2T4k
model and visual inspection showed that 2T4k fits were
better than 1T2k fits (Figure 2).
Population mixed effects modelling of plasma and brain
kinetics with and without tariquidar co-administration
(R)-[
11C]verapamil kinetics in both plasma and brain
were further studied using mixed effects modelling by
NONMEM. The final model is shown in Figure 3 and
the model diagnostics plots are shown in Figure 4. Com-
plete metabolite corrected plasma curves were best
described with a three compartment model. There were
no significant differences between kainate and saline
treated rats (Table 3). Tariquidar co-administration
however, resulted in an increased volume of distribution
(the pharmacokinetic term) for one of the peripheral
compartments (Vp1), whilst rat body weight affected
clearance (CL). Thus, tariquidar co-administration and
r a tw e i g h tw e r ei n c l u d e da sc o v a r i a t e sf o rV p1 and CL,
respectively.
Brain kinetics were best described with a two com-
partment model. Two covariates were included in the
brain model: tariquidar co-administration and rat group,
i.e. saline or kainate treated. Tariquidar co-administra-
tion increased both the transport into the brain, Qin,
and the volume of distribution in the brain, Vbr1,o f
(R)-[
11C]verapamil, whilst rat group affected only the
Vbr1 estimate. Both tariquidar co-administration and rat
group were treated as categorical covariates, i.e. they
were assigned a value of 0 or 1. The final equations,
including covariates were defined as:


ip o p weight ariate =∗ (/ . ) cov 308 4 (4)
  ip o p a r i a t e
COVARIATE or =∗ cov
() 10 (5)
Where θcovariate is the estimated covariate for weight
influence on CL (Equation 4) and for tariquidar co-
administration or rat group influence on Vp1,Q in or
Vbr1 (Equation 5). In Equation 5, tariquidar co-adminis-
tration and kainate treatment were assigned the value of
1, while vehicle co-administration and saline treatment
were assigned the value of 0. Thus, θcovariate is the frac-
tional change caused by kainate treatment or tariquidar
co-administration.
Figure 2 Logan (left), 1T2k (middle) and 2T4k (right) fits for a vehicle (upper panel) and a tariquidar (lower panel) co-administered
saline treated rat. Circles represent measured concentrations, solid lines best fits. The 2T4k model resulted in better fits than the 1T2k model
for most of the rats.
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Page 8 of 16Inter-individual variation was investigated for all para-
meters, but incorporated only for those parameters for
which it significantly (ΔOFV > 3.83) improved the
model (Table 3). Reparameterisation of CL into rate
constants (Table 2) was used to allow for comparison
with the other modelling approaches, and showed that
tariquidar co-administration increased the rate constant
for (R)-[
11C]verapamil transport into the brain, K1, and
Figure 3 The final population model.V c,V p1,a n dV p2 are pharmacological volumes of distribution in central and two peripheral plasma
compartments, respectively. Vbr1 and Vbr2 are volumes of distribution in central and peripheral brain compartment, respectively. CL, Q1,Q 2,Q in,
Qout and Qbr are total body clearance, bidirectional clearance between plasma and peripheral compartment 1, bidirectional clearance between
plasma and peripheral compartment 2, clearance into and out of the brain, and bidirectional clearance between central and peripheral brain
compartments respectively. The plus-sign indicates an increase in affected parameter estimate, i.e. tariquidar co-administration increased
peripheral plasma volume of distribution (Vp1), influx clearance to the brain (Qin) and brain volume of distribution (Vbr1), animal weight increased
systemic clearance (CL), and the kainate treatment increased Vbr1.
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Page 9 of 16decreased its rate constant for transport out of the
brain, k2, in both saline and kainate treated rats. In addi-
tion, since kainate treated rats had a higher brain distri-
bution volume (Vbr1), k2 was reduced in kainate
compared to saline treated rats. All these findings were
in accordance with those obtained using the other mod-
elling approaches, but the variation in parameter esti-
mates was smaller.
18FDG brain uptake
At 60 minutes after injection,
18FDG brain uptake was
significantly decreased in kainate treated rats compared
to saline treated rats (p < 0.05), with SUV (mean ± s.d.)
of 2.0 ± 0.4 and 1.6 ± 0.3, respectively. No change in
18FDG brain uptake could be demonstrated after tariqui-
dar co-administration. SUV was 1.8 ± 0.4 in both
groups. The same trend was seen in the cerebellum.
Figure 4 Diagnostic plots for the final population model including both brain and plasma (R)-[
11C]verapamil concentrations.A l ld o t s
represent individual data points and the lines (upper panels) identity lines. Observed versus population and individual predictions are shown in
the upper panels, respectively. Most of the data points are randomly distributed around the line of identity which indicates that the model
describes the concentrations adequately. Absolute individual weighted residuals versus individual predictions and weighted residuals versus time
are shown in the lower panels. Except for some outliers at early time points, most residuals are clustered around zero.
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Page 10 of 16P-gp expression
P-gp expression was measured immunohistochemically
and determined as P-gp labelled surface area and optical
density. Results are shown in Figure 5 and 6. The area
method showed a trend towards higher P-gp expression
in kainate treated rats, although the large variation
resulted in a non significant difference when groups
were compared with the student’s t-test (p > 0.05). The
optical density method showed no difference, not even a
trend, in P-gp expression between saline and kainate
treated rats.
In summary, all data analysis approaches indicated
only modest differences in brain distribution of (R)-[
11C]
verapamil between saline and kainate treated rats. The
most significant difference was in the transport rate of
(R)-[
11C]verapamil into the brain (K1 and Qin). However,
this difference was only significant in the tariquidar trea-
ted groups. (R)-[
11C]verapamil kinetics were best
described with a two compartment plasma and two
compartment brain model. Tariquidar co-administration
resulted mainly in an increase of (R)-[
11C]verapamil
transport into the brain. NONMEM provided most pre-
cise parameter estimates. P-gp expression was found to
be similar for kainate and saline treated rats.
Discussion
In this study the P-gp substrate (R)-[
11C]verapamil was
used in rats to investigate P-gp function at the BBB at 7
days following saline injection (control) and induction of
status epilepticus (SE) by kainate. To the best of our
knowledge, this is the first PET study of P-gp function
at the BBB of kainate treated rats. In addition, it is also
the first study in which PET data were analyzed both on
individual data profiles using kinetic models as used
routinely by the PET community, and with population
mixed effects modelling, as used in the pharmacokinetic
and pharmacokinetic-pharmacodynamic research field.
It has been hypothesized that P-gp expression is upre-
gulated in epilepsy and hence contributes to the devel-
opment of pharmacoresistance [10-12,21,52,53]. In the
present study co-administration of (R)-[
11C]verapamil
with vehicle showed no or only small BBB transport dif-
ferences between saline and kainate treated rats. (R)-
[
11C]verapamil uptake in the brain was very low in both
groups. A small increase in P-gp expression/function
and thereby also a small decrease in (R)-[
11C]verapamil
uptake in kainate treated rats might not be detectable
d u et ot h ea l r e a d yl o wb a s e l i n eo f(R)-[
11C]verapamil in
saline treated (control) rats. Further, due to the low
baseline signal and scanner resolution the analysis was
done on a whole brain region and hence possible regio-
nal differences between kainate treated and non-treated
rats could therefore not be investigated.
In the present study rats were scanned one week after
induction of SE by kainate. This time point was chosen
because previous studies indicated that the most pro-
nounced P-gp expression was expected around this time
[24]. However, at this time point in the present study,
immunohistochemical staining of P-gp expression in the
hippocampus revealed only a small trend in kainate
Table 3 Population parameter estimates using mixed effects modelling (standard deviation)
Parameter estimates Estimate Inter-individual variability Covariate tariquidar Covariate kainate Covariate weight
Plasma
Vc (mL) 22.8 (2.41) 0.175 (0.085) - - -
Vp1 (mL) 504 (40.7) 1.20 (0.119) - -
Vp2 (mL) 70.2 (9.91) 0.036 (0.034) - - -
CL (mL· min
-1) 14.7 (0.681) 0.065 (0.016) - - 1.98 (0.362)
Q1 (mL· min
-1) 16.1 (1.75) 0.220 (0.073) - - -
Q2 (mL· min
-1) 22.7 (3.34) 0.220 (0.073) - - -
Brain --
Vbr1 (mL) 7.23 (2.00) 0.115 (0.054) 2.41 (0.505) 1.32 (0.416) -
Vbr2 (mL) 10.7 (2.22) 0.115 (0.054) - - -
Qin (mL· min
-1) 1.75 (0.26) - 12.0 (0.554) - -
Qout (mL· min
-1) 1.81 (0.283) - - - -
Qbr (mL· min
-1) 0.692 (0.143) - - - -
Residual errors -- -
blood 0.118 (0.0152) - - - -
brain 0.226 (0.0354) - - - -
Covariates for tariquidar co-administration and rat group were defined as θcovariate
COVARIATE , where the COVARIATEs, i.e. kainate treatment or tariquidar co-
administration was 1 and saline treated or vehicle co-administration 0. The numbers reported are thus the fractional differences.
Covariate for weight was defined as (weight/0.3084)
θcovariate , where weight represent the individual animal’s weight in kg and 0.3084 was the average weight
among all animals. See also equations 4 and 5.
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Page 11 of 16treated rats. This was in line with P-gp functionality
measured using PET, i.e. no or very small differences
between the two groups. Bankstahl et al reported
increase in P-gp expression at 2 days post SE induced
by pilocarpine and amygdala stimulation but not at 7
days post SE [20]. On the other hand van Vliet et al,
who induced SE by electrical stimulation in the dentate
gyrus, and by pilocarpine reported prominent increase
on both time points [6,24]. These variable results may
thus be caused by the use of different animal models
and differences experimental conditions. Further, differ-
ent staining protocols emphasize P-gp expression in dif-
ferent cell types in the brain [41]. The immunostaining
used in this study shows P-gp expression in the
endothelial cells of the BBB.
Previous studies using the kainate model have shown
that spontaneous seizures start to occur in the majority
of rats at 3-4 weeks after SE [23]. Thus, due to the pre-
sent experimental design at 7 days after induction SE by
kainate it was not possible to state with certainty that
the rats would develop spontaneous seizures. Neverthe-
less, although seizures were not yet present (apart from
a few incidental observations), it can be assumed that at
this time point after SE the brain is progressing towards
the epileptic state. Furthermore, it is a common clinical
observation that
18FDG uptake is decreased in epileptic
brain tissue [54]. Actually, that is also what was found
in this study: a lower
18FDG brain uptake in kainate
compared to saline treated rats. Therefore, this indicates
that at least some functional changes were brought
about in the kainate treated rats that mimics what has
been observed in the human epileptic brain.
Overall, parameter estimates were similar for indivi-
dual and population modelling approaches. However,
for the same model complexity, mixed effects modelling
provided more precise parameter estimates. This is
because in population modelling, the inter-animal varia-
bility is incorporated separately from the structural
model parameters. A two (tissue) compartment brain
model best described cerebral kinetics of (R)-[
11C]
Figure 5 Staining of P-glycoprotein in the brain capillaries in the region of hippocampus. The arrows indicate the stained capillaries in a
kainate treated animal.
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Page 12 of 16verapamil. This is in line with previous reports using
(R)-[
11C]verapamil in combination with a P-gp inhibitor
in rats [26,28,55].
Tariquidar treatment was incorporated as a catego-
rical rather than continuous covariate in the popula-
tion model. This was justified, as differences in
plasma tariquidar concentrations were small and no
relation between the brain-to-plasma concentration
ratio, Kp, and plasma tariquidar concentration was
observed. Tariquidar treatment resulted in approxi-
mately an 11-fold increase in Kp.T h i si si na g r e e m e n t
with previous studies performed in naive (control)
rats using either tariquidar or cyclosporine A as P-gp
inhibitor [25-28].
Figure 6 Mean P-gp expression measured as P-gp labelled area (upper panel) and optical density (lower panel) at 7 days after saline
(n = 20) or kainate treatment (n = 22). Vertical bars represent standard deviation. There was no significant difference between the two rat
groups, but the P-gp labelled area tended to be somewhat larger for kainate treated rats.
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Page 13 of 16Since P-gp is expressed at the BBB, an upregulation of
P-gp function, as speculated in epilepsy, could either
decrease the clearance into the brain, Qin,o ri n c r e a s e
the clearance out from the brain, Qout. However, inclu-
sion of rat group (saline or kainate treated) as covariate
on the parameter Qin (which is related to K1,t h ep a r a -
meter usually used to describe the blood to brain trans-
fer of PET ligands, as K1 =Q in/Vc *Vc/Vbr1+2)o ro nt h e
parameter Qout did not improve the population model
fit. Instead, inclusion of rat group as covariate for the
brain distribution volume, Vbr1, did improve the model
fit significantly and increased Vbr1 with 32% in kainate
treated compared to saline treated rats. Therefore, these
data do not provide evidence of increased P-gp expres-
sion or functionality at the BBB at the time point after
kainate treatment chosen in this study. However, in the
brain P-gp is not only expressed at the endothelial cells
of the BBB but also at other cell types within the brain
[56]. If the kainate treatment would indeed have
resulted in increased P-gp expression on brain parench-
ymal cells, then inhibition of P-gp expressed in brain
parenchymal cells in kainate treated rats could cause a
larger intracellular distribution, compared to control
rats. As a consequence a Vbr1 would increase. This was
indeed found for (R)-[
11C]verapamil in the brain of kai-
nate treated rats in the present study: the increase in
Vbr1 resulted in a slower elimination of (R)-[
11C]verapa-
mil from the brain. However, as PET cannot distinguish
between extracellular and intracellular (R)-[
11C]verapa-
mil the PET data may only indicate increased intracellu-
lar distribution. Microdialysis would be the method of
choice to investigate intra-brain distribution further. In
this context, the findings of Bankstahl et al. are of inter-
est, as they reported that after SE, total brain to plasma
ratio of phenytoin in rats was lower, while the opposite
was found in brain dialysate to plasma ratio [20]. As dis-
cussed previously (R)-[
11C]verapamil is the most fre-
quently used radiotracer for studying P-gp function with
PET. Recently a new radiotracer, [N-methyl-
11C]N-des-
methyl-loperamide has been developed [57]. This radio-
tracer could potentially be better suited for studying
P-gp function since it produces less radiolabelled meta-
bolites compared to (R)-[
11C]verapamil and hence gives
a purer signal. The problem with a low baseline signal
still remains with this novel tracer. Bartmann et al used
the 5HT1A receptor ligand [
18F]MPPF (fluorine-18-
labeled4-(2;-methoxyphenyl)-1-[2;-(N-2"-pirydynyl)-p
fluorobenzamido]ethylpiperazine) to study brain uptake
in a chronic rat model of epilepsy and found that tari-
quidar treatment increased the transport into and
decreased the transport out from the brain more in AED
non-responders compared to AED responder rats [58].
This is in line with the notion that AED non-responders
have an increased P-gp functionality compared to AED
responders. The advantage of using a receptor ligand
such as [
18F]MPPF is that the baseline brain penetration
is higher compared to (R)-[
11C]verapamil and [N-methyl-
11C]N-desmethyl-loperamide. However, binding to
receptors within the brain might potentially confound
the results.
Finally, changes in blood flow due to tariquidar treat-
ment or disease state could potentially confound the
results if brain distribution of (R)-[
11C]verapamil would
be limited by blood flow. There are, however, no studies
indicating that tariquidar would alter blood flow and
there are no studies comparing blood flow in kainate
treated rats compared to controls.
Conclusions
In tariquidar co-administered animals, a decrease in
brain uptake of (R)-[
11C]verapamil was observed in kai-
nate treated compared to saline treated rats in an early
phase of 7 days following induction of SE. However, the
clearance out of the brain was also slower in the kainate
treated rats, resulting in similar brain-to-blood ratios
(Kp) for both groups. No significant changes in P-gp
expression were found. Further investigations have to
show if P-gp expression/functionality is altered in a later
stage of epilepsy development.
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